PoseidonDCM: PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

• Sponsor: Joshua M Hare (Other)
• Overall Status: Completed
• CT.gov ID: NCT01392625
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI) (NIH)
• Enrollment: 37
• Location: 1
• Arms: 2
• Actual Duration (Months): 75.3
• Patients Per Site Per Month: 0.5

Study Details

Study Description

Brief Summary

The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty1, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional myocardium2-4. Ideally, graft cells should be readily available, easy to culture to ensure adequate quantities for transplantation, and able to survive in host myocardium; often a hostile environment of limited blood supply and immunorejection. Whether effective cellular regenerative strategies require that administered cells differentiate into adult cardiomyocytes and couple electromechanically with the surrounding myocardium is increasingly controversial and recent evidence suggests that this may not be required for effective cardiac repair. Most importantly, transplantation of graft cells should improve cardiac function and prevent adverse ventricular remodeling. To date, a number of candidate cells have been transplanted in experimental models, including fetal and neonatal cardiomyocytes5, embryonic stem cell-derived myocytes6, 7, tissue engineered contractile grafts8, skeletal myoblasts9, several cell types derived from adult bone marrow10-15, and cardiac precursors residing within the heart itself16. There has been substantial clinical development in the use of whole bone marrow and skeletal myoblast preparations in studies enrolling both post-infarction patients, and patients with chronic ischemic left ventricular dysfunction and heart failure. The effects of bone-marrow derived mesenchymal stem cells (MSCs) have also been studied clinically.

Currently, bone marrow or bone marrow-derived cells represent highly promising modality for cardiac repair. The totality of evidence from trials investigating autologous whole bone marrow infusions into patients following myocardial infarction supports the safety of this approach. In terms of efficacy, increases in ejection fraction are reported in the majority of the trials.

Non-ischemic dilated cardiomyopathy is a common and problematic condition; definitive therapy in the form of heart transplantation is available to only a tiny minority of eligible patients. Cellular cardiomyoplasty for chronic heart failure has been studied less than for acute MI, but represents a potentially important alternative for this disease.

Condition or Disease	Intervention/Treatment	Phase
Non-ischemic Dilated Cardiomyopathy	Biological: Autologous hMSCs; Biological: Allogeneic hMSCs	Phase 1/Phase 2

Detailed Description

This is a Pilot Study, intended as a safety assessment prior to a full comparator study. In this Pilot Study, cells administered via the Biosense Webster MyoStar NOGA injection catheter system will be tested in 36 patients in two groups:

Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 X 108 (100 million) Auto-hMSCs.

Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 X 108 (100 million) Auto-hMSCs.

The first three (3) patients in each group (Group 1 and Group 2) will not be treated less than 5 days apart and will each undergo full evaluation for 5 days to demonstrate there is no evidence of a procedure induced myocardial infarction or myocardial perforation prior to proceeding with the treatment of further patients.

Patients will be randomized in a 1:1 ratio to one of the two groups.

Treatment Strategies: Autologous hMSCs vs. Allogeneic hMSCs. The Study Team will record and maintain a detailed record of injection locations.

If a patient is randomized to Groups 1 (Auto-hMSCs) and the Auto-hMSCs do not expand to the required dose of 1 X 108 cells, each injection will contain the maximum number of cells available.

The injections will be administered transendocardially during cardiac catheterization using the Biosense Webster MyoStar NOGA Catheter System.

For patients randomized to Group 1(Auto-hMSCs); the cells will be derived from a sample of the patient's bone marrow (obtained by iliac crest aspiration) approximately 4-6 weeks prior to cardiac catheterization. For patients randomized to Group 2 (Allo- hMSCs), the cells will be supplied from an allogeneic human mesenchymal stem cell source manufactured by the University of Miami. The Allo-hMSCs for patients in group 2 will be administered after all baseline assessments are completed with an expected range of 2 - 4 weeks post-randomization.

Following cardiac catheterization and cell injections, patients will be hospitalized for a minimum of 2 days then followed at 2 weeks post-catheterization, and at month 2, 3, 6, and 12 to complete all safety and efficacy assessments.

Study Design

• Study Type: Interventional
• Actual Enrollment: 37 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Participant)
• Primary Purpose: Treatment
• Official Title: A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Dilated Cardiomyopathy.
• Actual Study Start Date: May 19, 2011
• Actual Primary Completion Date: Aug 28, 2016
• Actual Study Completion Date: Aug 28, 2017

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Autologous hMSCs Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	Biological: Autologous hMSCs; Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.; Other Names: Biosense Webster MyoStar NOGA Injection Catheter System.
Active Comparator: Allogeneic hMSCs Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	Biological: Allogeneic hMSCs; Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.; Other Names: Biosense Webster MyoStar NOGA Injection Catheter System.

Outcome Measures

Primary Outcome Measures

1. Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs) [One month post-catheterization]

   Incidence of TE-SAEs is defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise), or any other potential late effects detected and corroborated by clinical presentation, laboratory investigations, image analysis and when necessary with biopsy from suspected target sites in the body.

Secondary Outcome Measures

1. Measurement of Changes in Peak VO2 [Baseline, 6 month and 12 month]

   Measurement of Peak oxygen consumption (Peak VO2) by treadmill determination during the 12 month follow-up period.

2. Measurement of Changes in 6 Minute Walk [Baseline, 6 month and 12 month]

   Measurement of Six-minute walk test during the 12 month follow-up period

3. Measurement of Changes in Global Ejection Fraction [Baseline, 6 month and 12 month]

   Measurement of regional left ventricular function, end diastolic and end systolic volume, measured by MRI, and or CT, and echocardiogram.

4. Measurement of Changes in New York Heart Association (NYHA) [Baseline, 6 month and 12 month]

   Measurement of New York Heart Association (NYHA) functional class during the 12 month follow-up period.

5. Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire [Baseline, 6 month and 12 month]

   Measurement of Minnesota Living with Heart Failure (MLHF) Questionnaire during the 12 month follow-up period. It measures the effects of symptoms, functional limitations, and psychological distress on an individual's quality of life. The response scale for all 21 items on the MLHF is based on a 6-point. The Maximum possible scores being 126 and the minimum 0. Higher scores indicate a worse or worsening quality of life, while lower scores or decreasing scores indicate a better quality of life.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 95 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Major Inclusion Criteria:

• Be ≥ 18 and < 95 years of age.

• Provide written informed consent.

• Diagnosis of nonischemic dilated cardiomyopathy.

• Be a candidate for cardiac catheterization within 5 to 10 weeks of screening.

• Been treated with appropriate maximal medical therapy for heart failure.

• Ejection fraction below 40% and either a left ventricular end diastolic diameter (LVEDD) > 5.9cm in male subjects, an LVEDD of > 5.6cm in female subjects or left ventricular end diastolic volume index > 125 mL/m2

• Be able to undergo an MRI or CT.

Major Exclusion Criteria:

• Baseline glomerular filtration rate equal or < 45 ml/min/1.73m2.

• Be eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of nonischemic dilated cardiomyopathy.

• Presence of a prosthetic aortic valve or heart constrictive device.

• Presence of a prosthetic mitral valve.

• Previous myocardial infarction (MI) as documented by a clinical history that will include an elevation of cardiac enzymes and/or ECG changes consistent with MI.

• Diagnosis of nonischemic dilated cardiomyopathy due to valvular dysfunction, mitral regurgitation, tachycardia, or myocarditis.

• Previous treatment for post-infarction left ventricular dysfunction including PCI and thrombolytic therapy.

• Documented presence of a known LV thrombus, aortic dissection, or aortic aneurysm.

• Documented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries.

• Documented presence of aortic stenosis (aortic stenosis graded as 1.5cm2 or less).

• Documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).

• Evidence of a life-threatening arrhythmia in the absence of a defibrillator (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete second or third degree heart block in the absence of a functioning pacemaker) or QTc interval > 550 ms on screening ECG.

• AICD firing in the past 30 days prior to the procedure

• Be eligible for or require coronary artery revascularization.

• Diabetic with poorly controlled blood glucose levels and/or evidence of proliferative retinopathy.

• Have a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet values < 100,000/ul without another explanation.

• Have liver dysfunction, as evidenced by enzymes (ALT and AST) greater than three times the ULN.

• Have a coagulopathy condition = (INR > 1.3) not due to a reversible cause.

• Known, serious radiographic contrast allergy.

• Known allergies to penicillin or streptomycin.

• Organ transplant recipient.

• Have a history of organ or cell transplant rejection

• Clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.

• Non-cardiac condition that limits lifespan to < 1 year.

• On chronic therapy with immunosuppressant medication.

• Serum positive for HIV, hepatitis BsAg, or viremic hepatitis C.

• Female patient who is pregnant, nursing, or of child-bearing potential and not using effective birth control.

• Have a history of drug or alcohol abuse within the past 24 months.

• Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Miami School of Medicine	Miami	Florida	United States	33136

Sponsors and Collaborators

• Joshua M Hare
• National Heart, Lung, and Blood Institute (NHLBI)

Investigators

• Principal Investigator: Joshua M Hare, MD, University of Miami

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Interdisciplinary Stem Cell Institute University of Miami

Publications

• Hare JM, DiFede DL, Rieger AC, Florea V, Landin AM, El-Khorazaty J, Khan A, Mushtaq M, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Alfonso CE, Valasaki K, Pujol MV, Golpanian S, Ghersin E, Fishman JE, Pattany P, Gomes SA, Delgado C, Miki R, Abuzeid F, Vidro-Casiano M, Premer C, Medina A, Porras V, Hatzistergos KE, Anderson E, Mendizabal A, Mitrani R, Heldman AW. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol. 2017 Feb 7;69(5):526-537. doi: 10.1016/j.jacc.2016.11.009. Epub 2016 Nov 14.
• Trachtenberg B, Velazquez DL, Williams AR, McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz R, Mendizabal A, Oskouei B, Byrnes J, Soto V, Tracy M, Zambrano JP, Heldman AW, Hare JM. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J. 2011 Mar;161(3):487-93. doi: 10.1016/j.ahj.2010.11.024.
• Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman AW, Hare JM. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res. 2011 Apr 1;108(7):792-6. doi: 10.1161/CIRCRESAHA.111.242610. Epub 2011 Mar 17.

• Responsible Party: Joshua M Hare, Sponsor- Investigator; Director of ISCI, Chief Science Officer, University of Miami
• ClinicalTrials.gov Identifier: NCT01392625
• Other Study ID Numbers: 20100968; 1R01HL110737-01
• First Posted: Jul 12, 2011
• Last Update Posted: Feb 15, 2018
• Last Verified: Jan 1, 2018

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Joshua M Hare, Sponsor- Investigator; Director of ISCI, Chief Science Officer, University of Miami: Non ischemic dilated cardiomyopathy; Dilated cardiomyopathy; Heart failure; Cardiac Stem Cell Transplantation; Stem Cells
• Additional relevant MeSH terms: Cardiomyopathies; Cardiomyopathy, Dilated

Study Results

Participant Flow

Arm/Group Title	Autologous hMSCs	Allogeneic hMSCs
Arm/Group Description	Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Autologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Allogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
Period Title: Overall Study
STARTED	18	19
COMPLETED	16	18
NOT COMPLETED	2	1

Baseline Characteristics

Arm/Group Title	Autologous hMSCs	Allogeneic hMSCs	Total
Arm/Group Description	Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Autologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Allogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	Total of all reporting groups
Overall Participants	18	19	37
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	57.4 (11.0)	54.4 (11.5)	55.8 (11.2)
Sex: Female, Male (Count of Participants)
Female	7 38.9%	5 26.3%	12 32.4%
Male	11 61.1%	14 73.7%	25 67.6%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	8 44.4%	4 21.1%	12 32.4%
Not Hispanic or Latino	10 55.6%	15 78.9%	25 67.6%
Unknown or Not Reported	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	0 0%	0 0%	0 0%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	1 5.6%	2 10.5%	3 8.1%
White	16 88.9%	17 89.5%	33 89.2%
More than one race	0 0%	0 0%	0 0%
Unknown or Not Reported	1 5.6%	0 0%	1 2.7%
Participants Injection status in the trial (Count of Participants)
No	2 11.1%	1 5.3%	3 8.1%
Yes	16 88.9%	18 94.7%	34 91.9%
Participants Ejection Fraction % in the trial (percentage) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [percentage]	21.7 (6.2)	22.5 (6.5)	22.1 (6.3)
Enrollment End Diastolic diameter (CM) (centimeters) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [centimeters]	7.0 (1.6)	7.2 (1.2)	7.1 (1.4)
New York Heart Association Class (Count of Participants)
Class I - no limitation	6 33.3%	4 21.1%	10 27%
Class II - Slight Limitation of Physical Activity	8 44.4%	9 47.4%	17 45.9%
Class III - Marked Limitation of Physical Activity	2 11.1%	5 26.3%	7 18.9%
Class IV -Inability to carry on physical activity	0 0%	0 0%	0 0%

Outcome Measures

1. Primary Outcome

Title	Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)
Description	Incidence of TE-SAEs is defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise), or any other potential late effects detected and corroborated by clinical presentation, laboratory investigations, image analysis and when necessary with biopsy from suspected target sites in the body.
Time Frame	One month post-catheterization

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Autologous hMSCs	Allogeneic hMSCs
Arm/Group Description	Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Autologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Allogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
Measure Participants	16	18
Upper respiratory tract infection	1 5.6%	0 0%
Ventricular tachycardia	0 0%	1 5.3%
Device Pacing issue	0 0%	1 5.3%

2. Secondary Outcome

Title	Measurement of Changes in Peak VO2
Description	Measurement of Peak oxygen consumption (Peak VO2) by treadmill determination during the 12 month follow-up period.
Time Frame	Baseline, 6 month and 12 month

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Autologous hMSCs	Allogeneic hMSCs
Arm/Group Description	Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Autologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Allogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
Measure Participants	16	18
Peak VO2 (Baseline)	16.0 (5.13)	17.9 (5.17)
Peak VO2 (6 months)	15.5 (6.62)	17.6 (3.55)
Peak VO2 (1 year)	16.4 (3.92)	20.1 (5.10)

3. Secondary Outcome

Title	Measurement of Changes in 6 Minute Walk
Description	Measurement of Six-minute walk test during the 12 month follow-up period
Time Frame	Baseline, 6 month and 12 month

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Autologous hMSCs	Allogeneic hMSCs
Arm/Group Description	Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Autologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Allogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
Measure Participants	16	18
6 minute walk (Baseline)	416.4 (105.74)	427.2 (67.35)
6 minute walk (6 months)	384.2 (106.96)	438.7 (106.53)
6 minute walk (1 year)	32.3 (12.71)	35.1 (13.59)

4. Secondary Outcome

Title	Measurement of Changes in Global Ejection Fraction
Description	Measurement of regional left ventricular function, end diastolic and end systolic volume, measured by MRI, and or CT, and echocardiogram.
Time Frame	Baseline, 6 month and 12 month

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Autologous hMSCs	Allogeneic hMSCs
Arm/Group Description	Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Autologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Allogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
Measure Participants	16	18
Global ejection fraction (Baseline)	25.2 (10.49)	37.6 (9.03)
Global ejection fraction (1 year)	32.3 (12.71)	35.1 (13.59)

5. Secondary Outcome

Title	Measurement of Changes in New York Heart Association (NYHA)
Description	Measurement of New York Heart Association (NYHA) functional class during the 12 month follow-up period.
Time Frame	Baseline, 6 month and 12 month

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Autologous hMSCs	Allogeneic hMSCs
Arm/Group Description	Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Autologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Allogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
Measure Participants	18	19
NYHA Class 1 (Baseline)	6 33.3%	4 21.1%
NYHA Class 2 (Baseline)	8 44.4%	9 47.4%
NYHA Class 3 (Baseline)	2 11.1%	5 26.3%
NYHA Class 1 (6 month)	8 44.4%	12 63.2%
NYHA Class 2 (6 month)	6 33.3%	4 21.1%
NYHA Class 3 (6 month)	1 5.6%	1 5.3%
NYHA Class 1 (12 month)	7 38.9%	14 73.7%
NYHA Class 2 (12 month)	2 11.1%	1 5.3%
NYHA Class 3 (12 month)	2 11.1%	0 0%

6. Secondary Outcome

Title	Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire
Description	Measurement of Minnesota Living with Heart Failure (MLHF) Questionnaire during the 12 month follow-up period. It measures the effects of symptoms, functional limitations, and psychological distress on an individual's quality of life. The response scale for all 21 items on the MLHF is based on a 6-point. The Maximum possible scores being 126 and the minimum 0. Higher scores indicate a worse or worsening quality of life, while lower scores or decreasing scores indicate a better quality of life.
Time Frame	Baseline, 6 month and 12 month

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Autologous hMSCs	Allogeneic hMSCs
Arm/Group Description	Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Autologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Allogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
Measure Participants	16	18
MLHF (Baseline)	30.5	38.0
MLHF (6 month)	35	18
MLHF (12 month)	9.0	12.0

Adverse Events

Time Frame	These AE's were collected over a period of 1 year from the subject signing the consent form.
Arm/Group Title	Autologous hMSCs		Allogeneic hMSCs
Arm/Group Description	Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Autologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.		Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Allogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
All Cause Mortality
	Autologous hMSCs		Allogeneic hMSCs
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/18 (11.1%)		0/19 (0%)
Serious Adverse Events
	Autologous hMSCs		Allogeneic hMSCs
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	6/18 (33.3%)		6/19 (31.6%)
Cardiac disorders
Ventricular tachycardia	0/18 (0%)	0	1/19 (5.3%)	1
Arrhythmia	0/18 (0%)	0	1/19 (5.3%)	1
Cardiac failure	2/18 (11.1%)	3	1/19 (5.3%)	1
Coronary artery disease	1/18 (5.6%)	1	0/19 (0%)	0
Ventricular tachycardia	0/18 (0%)	0	1/19 (5.3%)	1
Gastrointestinal disorders
Gatrooesophageal reflux disease	0/18 (0%)	0	1/19 (5.3%)	1
Infections and infestations
Upper respiratory tract infection	1/18 (5.6%)	1	0/19 (0%)	0
Upper respiratory tract infection	1/18 (5.6%)	1	0/19 (0%)	0
Injury, poisoning and procedural complications
Subdural heamatoma	1/18 (5.6%)	1	0/19 (0%)	0
Nervous system disorders
Syncope	1/18 (5.6%)	1	0/19 (0%)	0
Product Issues
Device Pacing issue	0/18 (0%)	0	1/19 (5.3%)	1
Device pacing issues	0/18 (0%)	0	1/19 (5.3%)	1
Respiratory, thoracic and mediastinal disorders
Dyspnoea	0/18 (0%)	0	1/19 (5.3%)	1
Skin and subcutaneous tissue disorders
Angioedema	0/18 (0%)	0	1/19 (5.3%)	1
Other (Not Including Serious) Adverse Events
	Autologous hMSCs		Allogeneic hMSCs
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	4/18 (22.2%)		7/19 (36.8%)
Blood and lymphatic system disorders
Anemia	0/18 (0%)	0	1/19 (5.3%)	1
Cardiac disorders
Mitral valve incompetence	1/18 (5.6%)	1	0/19 (0%)	0
Ventricular tachycardia	0/18 (0%)	0	1/19 (5.3%)	1
General disorders
Adverse drug reaction	0/18 (0%)	0	1/19 (5.3%)	1
Chest Discomfort	0/18 (0%)	0	1/19 (5.3%)	1
Infections and infestations
Upper respiratory tract infection	1/18 (5.6%)	1	1/19 (5.3%)	1
Vulvovaginal mycotic infection	0/18 (0%)	0	1/19 (5.3%)	1
Investigations
Electrocardiogram abnormal	0/18 (0%)	0	1/19 (5.3%)	1
Weight increased	2/18 (11.1%)	2	0/19 (0%)	0
Nervous system disorders
Dizziness	0/18 (0%)	0	1/19 (5.3%)	1
Migraine	0/18 (0%)	0	1/19 (5.3%)	1
Product Issues
Device pacing issue	0/18 (0%)	0	1/19 (5.3%)	1
Respiratory, thoracic and mediastinal disorders
Dyspnoea	1/18 (5.6%)	1	0/19 (0%)	0
Wheezing	1/18 (5.6%)	1	0/19 (0%)	0
Surgical and medical procedures
Implantable defibrillator insertion	0/18 (0%)	0	1/19 (5.3%)	1

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.